All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: CFAD-0.2 (for 10mM×0.2ml)

Cat. No.: CFAD-25 (for 25mg)

Cat. No.: CFAD-100 (for 100mg)

Description

Caffeic acid acts as an inhibitor for both the TRPV1 ion channel and 5-Lipoxygenase (5-LO).

Basic Information

• Aliases: 3,4-Dihydroxycinnamic acid
• Source: Taraxacum mongolicum Hand.-Mazz.; Citrus limon (L.) Burm. f.
• Compound type: Phenylpropanoids > Phenylpropanoic acids
• Chemical Formula: C₉H₈O₄
• Molecular Weight: 180.16
• CAS Number: 331-39-5
• Purity: 98%, HPLC
• Solvent/Solubility: DMSO: 100 mg/mL (555.06 mM); Water: < 0.1 mg/mL (insoluble)
• Solution Preparation: Add 2mg to 1.11ml of DMSO, or add 1.80mg to 1ml of DMSO, to prepare a 10mM solution.

Signaling Pathway

-

In Vitro Study

Caffeic acid exhibits inhibitory effects on histamine-induced responses, with the extent of inhibition increasing gradually as the pretreatment concentration escalates from 0.1 to 1 mM, mirroring typical dose-dependent patterns. Pretreatment of HEK293T-TRPV1 cells with 1 mM Caffeic acid leads to a significant reduction in capsaicin-induced responses, whereas lower concentrations show less pronounced inhibitory effects. Calcium imaging experiments reveal that incubation with Caffeic acid markedly inhibits histamine-sensitive dorsal root ganglion (DRG) neurons. Specifically, pretreatment with 1 mM Caffeic acid reduces the percentage of responsive DRG neurons to histamine application from 12.5% to 2.1%. Moreover, pretreatment with 1 mM Caffeic acid effectively blocks allylisothiocyanate (AITC)-induced intracellular calcium increase in TRPA1-expressing cells and inhibits the activation of TRPA1 by AITC.

In Vivo Study

Mice pretreated with Caffeic acid at a dose of 500 mg/kg display significantly reduced histamine-induced scratching, with an average of 30.50±10.87 bouts per hour (n=6). However, the lower dose of Caffeic acid (100 mg/kg) does not exhibit significant anti-scratching effects in histamine-induced scratching, although there is a trend towards reduction, with an average of 49.40±12.35 bouts per hour (n=5). Moreover, pretreatment with 500 mg/kg of Caffeic acid significantly inhibits chloroquine-induced scratching, with an average of 161.6±31.42 bouts per hour (n=5).

Caffeic acid also demonstrates a dose-dependent reduction in the expression of 5-LO mRNA in the hippocampus, with a significant decrease observed (P<0.01). Compared to the ischemia-reperfusion (I/R) non-treated group, the I/R-Caffeic acid group, especially at a dose of 50 mg/kg, exhibits significantly reduced 5-LO protein expression (P<0.05 or P<0.01). Additionally, compared to the I/R non-treated group, both low- and high-dose Caffeic acid groups show significantly shortened latency to find the platform in behavioral testing (P<0.01). Notably, the most pronounced reduction in platform latency is observed in the I/R-Caffeic acid group at 50 mg/kg. In the low-dose Caffeic acid group, cell injury remains marked, with a pyknosis ratio of (63.6±2.8)%, whereas in the high-dose Caffeic acid group, hippocampal neuron karyopyknosis is significantly reduced, resulting in a pyknosis ratio of (13.3±3.0)%.

Clinical Trial

NCT02556814: Immune Thrombocytopenia, Phase 4; NCT02351622: Immune Thrombocytopenia, Phase 3; NCT04648917: Esophagus Cancer, Stage III, Phase 3.

Storage

Store at -20°C for at least one year. The solid powder is stable at 4°C for at least one month. If dissolved in a non-DMSO solvent, it is recommended to aliquot and store at -80°C for up to six months.

Precautions

• This product may have a certain degree of toxicity to the human body. Please take appropriate precautions to avoid direct contact with the body or inhalation.
• This product is for scientific research use only by professionals and is not intended for clinical diagnosis or treatment, food, or pharmaceutical purposes. It should not be stored in ordinary residential areas.
• For your safety and health, please wear laboratory attire and disposable gloves while handling.

Only for research and not intended for treatment of humans or animals

Journals Using SBS Genetech Products                                       Universities Using SBS Genetech Products

SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory